Simpler Grants.gov #RFA-CA-27-002

NCI Grant Solicitation for Emerging Cancer Research Technologies (R33)

This opportunity invites research organizations to apply for grants supporting the advanced development and validation of innovative technologies for cancer research, under the National Cancer Institute's IMAT Program. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Scope: - Solicitation for R33 grant applications focused on emerging technologies for basic and clinical cancer research - Technologies should offer novel capabilities for targeting, probing, analyzing, handling, or quality control of biospecimens - Eligibility: - Open to educational, governmental, business, nonprofit, tribal, and foreign organizations - Products/Services Requested: - No specific OEMs, vendors, products, or part numbers are identified - Emphasis on technology development and validation, not procurement of commercial products - Funding: - Total program funding: $4,500,000 - Individual awards: $50,000 to $300,000 - No cost sharing or matching required - Unique Requirements: - Projects must have already overcome feasibility gaps and now require further development and rigorous validation - Clinical trials are not allowed under this solicitation

Description

The National Cancer Institute (NCI) solicits grant applications for exploratory research projects focused on the development and validation of emerging technologies with novel capabilities for targeting, probing, analyzing, handling, or quality control of biospecimens used in basic or clinical cancer research. The solicitation targets R33 applications where major feasibility gaps have been overcome but further development and rigorous validation are needed to encourage adoption by the research community. The technologies should accelerate or enhance research in cancer biology, early detection, clinical diagnosis, treatment, control, epidemiology, or address cancer health disparities, with a focus on cancer applications. Projects applying existing technologies with novelty only in the biological or clinical target are not appropriate. This funding opportunity is part of the NCI Innovative Molecular Analysis Technologies (IMAT) Program.

View original listing